News from discovery laboratories, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-SMALL:DSCO)

Feb 03, 2016, 16:06 ET

Discovery Labs Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

 Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Feb 01, 2016, 16:01 ET

Discovery Labs Announces Appointment of New Chief Executive Officer and Provides an Update on AEROSURF® Phase 2 Program

Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory...

Jan 21, 2016, 16:10 ET

Discovery Labs Announces Reverse Stock Split

 Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has filed a Certificate of Amendment ("Amendment") to its Amended and...

Dec 29, 2015, 16:05 ET

Discovery Labs Announces Initiation of AEROSURF® Phase 2b Clinical Trial

 Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Dec 10, 2015, 07:30 ET

Results of AEROSURF® Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age Presented at the 2015 Hot Topics in Neonatology Annual Meeting

 Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that data from the AEROSURF® Phase 2a clinical program in premature infants...

Nov 12, 2015, 07:00 ET

Discovery Labs Announces Top Line Results of AEROSURF® Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age

 Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Nov 06, 2015, 08:30 ET

Discovery Labs to Announce Results from AEROSURF® Phase 2a Expansion Clinical Trial

 Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Nov 05, 2015, 16:15 ET

Discovery Labs Provides Business Update and Reports Third Quarter 2015 Financial Results

Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Oct 21, 2015, 07:30 ET

Discovery Labs Announces Completion of Enrollment in AEROSURF® Phase 2a Dose Expansion Trial

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Aug 10, 2015, 16:45 ET

Discovery Labs Provides Business Update and Reports Second Quarter 2015 Financial Results

 Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Aug 03, 2015, 16:15 ET

Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates

Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

Jul 30, 2015, 07:30 ET

Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury

 Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has received the second $1.0M tranche under a previously awarded Phase II...

Jul 22, 2015, 16:15 ET

Discovery Labs Announces Completion of $40.25 Million Public Offering

Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering of 16.3 million Series A...

Jul 17, 2015, 08:30 ET

Discovery Labs Announces Pricing of $35 Million Public Offering of Common Stock, Warrants and Pre-funded Warrants

 Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has priced an underwritten public offering of 18.3 Million Series A units...

Jul 16, 2015, 16:01 ET

Discovery Labs Announces Proposed Public Offering of Common Stock, Warrants and Pre-funded Warrants

Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has commenced an underwritten public offering of units.  Each unit will...

Jul 01, 2015, 07:30 ET

Discovery Labs Receives Nasdaq Notification Related to Minimum Bid Price

 Discovery Laboratories, Inc. (Nasdaq: DSCO) announced today that, on June 29, 2015, the Company received a letter from The Nasdaq Stock Market...

May 20, 2015, 07:30 ET

Discovery Labs Announces Enrollment of First Patient in AEROSURF® Phase 2a Dose Expansion Trial

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

May 14, 2015, 07:00 ET

Discovery Labs Announces Results of Phase 2a Clinical Trial of AEROSURF®

 Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

May 13, 2015, 11:34 ET

Discovery Labs to Announce Results from AEROSURF® Phase 2a Clinical Trial

 Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...

May 07, 2015, 16:05 ET

Discovery Labs Reports First Quarter 2015 Financial Results

 Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for...